<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-168</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ЛЕКАРСТВЕННЫХ СРЕДСТВ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>DRUG PRODUCTS EFFICACY AND SAFETY</subject></subj-group></article-categories><title-group><article-title>ИЗУЧЕНИЕ СРАВНИТЕЛЬНОЙ КИНЕТИКИ РАСТВОРЕНИЯ ЛЕКАРСТВЕННОГО ПРЕПАРАТА ВАЛСАРТАН II КЛАССА БИОФАРМАЦЕВТИЧЕСКОЙ КЛАССИФИКАЦИОННОЙ СИСТЕМЫ В СООТВЕТСТВИИ С ПРОЦЕДУРОЙ «БИОВЕЙВЕР»</article-title><trans-title-group xml:lang="en"><trans-title>DISSOLUTION PROFILE STUDIES OF BCS CLASS II DRUG VALSARTAN BY BIOWAIVER PROCEDURE</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бригас</surname><given-names>Е. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Brigas</surname><given-names>E. R.</given-names></name></name-alternatives><email xlink:type="simple">katekukushkina28@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Успенская</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Uspenskaya</surname><given-names>E. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Писарев</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Pisarev</surname><given-names>V. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова»</institution></aff><aff xml:lang="en"><institution>M.V. Lomonosov Moscow State University</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский университет дружбы народов»</institution></aff><aff xml:lang="en"><institution>People Friendship University of Russia</institution></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Научно-производственный центр «Пробиотек»</institution></aff><aff xml:lang="en"><institution>Scientific-production center “Probiotech”</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>09</day><month>01</month><year>2019</year></pub-date><volume>0</volume><issue>4</issue><fpage>152</fpage><lpage>157</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бригас Е.Р., Успенская Е.В., Писарев В.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Бригас Е.Р., Успенская Е.В., Писарев В.В.</copyright-holder><copyright-holder xml:lang="en">Brigas E.R., Uspenskaya E.V., Pisarev V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/168">https://www.pharmjournal.ru/jour/article/view/168</self-uri><abstract><p>Проведено сравнительное исследование кинетики растворения лекарственных препаратов валсартана в трех средах растворения, моделирующих основные разделы ЖКТ, с последующим количественным определением методом УФ-спектрофотометрии при длине волны 254 нм. Исследование проводили на аппарате «Лопастная мешалка», точки отбора соответствовали 5, 10, 15, 30 минутам. Полученные значения факторов подобия f2 подтвердили эквивалентность кинетики растворения и составляют: f2=67 в растворе хлористоводородной кислоты с pH 1,2, f2=57 в фосфатном буферном растворе с pH 4,5. В фосфатном буферном растворе с pH 6,8 через 15 минут в раствор перешло более 85% действующего вещества, поэтому профили эквивалентны без математической оценки.</p></abstract><trans-abstract xml:lang="en"><p>Drug release studies (or in vitro release) of valsartan in three dissolution media simulating the main sections of the gastrointestinal tract were conducted. The concentrations were determined using UV/Vis spectrophotometer (Varian Cary 50) at 254 nm. The study was conducted using dissolution apparatus with the paddle assemble; 5-mL sample aliquots were withdrawn at 5, 10, 15, and 30 min. Estimation f2 parameter confirmed the equivalence of valsartan dissolution kinetics: f2=67 in hydrochloric acid solution, pH 1,2; f2=57 in phosphate buffer, pH 4,5, and in phosphate buffer, pH 6,8 - dissolution amount is greater than 85% at 15 min, so the two products are deemed equivalent, and a profile comparison is not necessary.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>сравнительный тест кинетики растворения</kwd><kwd>биовейвер</kwd><kwd>валсартан</kwd></kwd-group><kwd-group xml:lang="en"><kwd>comparative dissolution profile</kwd><kwd>biowaiver</kwd><kwd>valsartan</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Стратегия развития фармацевтической промышленности Российской Федерации на период до 2020 года. Москва, 2009 г.</mixed-citation><mixed-citation xml:lang="en">Стратегия развития фармацевтической промышленности Российской Федерации на период до 2020 года. Москва, 2009 г.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">И.Е. Шохин. База данных по растворению FDA - незаменимый инструмент для разработчиков воспроизведенных ЛС (обзор) // Разработка и регистрация лекарственных средств. 2012. № 1(1). С. 3-12.</mixed-citation><mixed-citation xml:lang="en">И.Е. Шохин. База данных по растворению FDA - незаменимый инструмент для разработчиков воспроизведенных ЛС (обзор) // Разработка и регистрация лекарственных средств. 2012. № 1(1). С. 3-12.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. WHO Expert Committee on Specifications for Pharmaceutical Preparations. WHO Technical Report Series 937, 2006, annex 7.</mixed-citation><mixed-citation xml:lang="en">Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. WHO Expert Committee on Specifications for Pharmaceutical Preparations. WHO Technical Report Series 937, 2006, annex 7.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">И.Е. Смехова, Ю.М. Перова. Тест «Растворение» и современные подходы к оценке эквивалентности лекарственных препаратов (обзор) // Разработка и регистрация лекарственных средств. 2013. № 1(2). С. 50-61.</mixed-citation><mixed-citation xml:lang="en">И.Е. Смехова, Ю.М. Перова. Тест «Растворение» и современные подходы к оценке эквивалентности лекарственных препаратов (обзор) // Разработка и регистрация лекарственных средств. 2013. № 1(2). С. 50-61.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Д.Ю. Гребёнкин, Я.М. Станишевский, И.Е. Шохин. Современные подходы к проведению сравнительного теста кинетики растворения // Разработка и регистрация лекарственных средств. 2016. № 14.</mixed-citation><mixed-citation xml:lang="en">Д.Ю. Гребёнкин, Я.М. Станишевский, И.Е. Шохин. Современные подходы к проведению сравнительного теста кинетики растворения // Разработка и регистрация лекарственных средств. 2016. № 14.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Guidance for Industry. Bioavailability and Bioequivalence. Studies for Orally Administered Drug. Products - General Considerations. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), March 2003.</mixed-citation><mixed-citation xml:lang="en">Guidance for Industry. Bioavailability and Bioequivalence. Studies for Orally Administered Drug. Products - General Considerations. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), March 2003.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Н.А. Румянцев, А.С. Румянцев. Динамика потребления антигипертензивных препаратов в 2007-2013 гг. на территории Российской Федерации // Журнал прикладной фармакологии и персонализированной фармакотерапии. 2014. № 3. С. 18-26.</mixed-citation><mixed-citation xml:lang="en">Н.А. Румянцев, А.С. Румянцев. Динамика потребления антигипертензивных препаратов в 2007-2013 гг. на территории Российской Федерации // Журнал прикладной фармакологии и персонализированной фармакотерапии. 2014. № 3. С. 18-26.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">S. Beg, S. Swain. Development, Optimization, and Characterization of Solid Self-Nanoemulsifying Drug Delivery Systems of Valsartan Using Porous Carriers // AAPS PharmSciTech. 2012. № 13(4): P. 1416-1427.</mixed-citation><mixed-citation xml:lang="en">S. Beg, S. Swain. Development, Optimization, and Characterization of Solid Self-Nanoemulsifying Drug Delivery Systems of Valsartan Using Porous Carriers // AAPS PharmSciTech. 2012. № 13(4): P. 1416-1427.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System Guidance for Industry, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Biopharmaceutics Revision 1. U.S. Government Printing Office: Washington, DC, May 2015.</mixed-citation><mixed-citation xml:lang="en">Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System Guidance for Industry, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Biopharmaceutics Revision 1. U.S. Government Printing Office: Washington, DC, May 2015.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on the investigation of bioequivalence, Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, London, 20 January 2010.</mixed-citation><mixed-citation xml:lang="en">Guideline on the investigation of bioequivalence, Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, London, 20 January 2010.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Правила проведения исследований биоэквивалентности лекарственных средств Евразийского экономического союза. Версия 2.0 от 20.02.2015.</mixed-citation><mixed-citation xml:lang="en">Правила проведения исследований биоэквивалентности лекарственных средств Евразийского экономического союза. Версия 2.0 от 20.02.2015.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">International Pharmaceutical Federation (FIP), Biowaiver Monographs 2004-2012.</mixed-citation><mixed-citation xml:lang="en">International Pharmaceutical Federation (FIP), Biowaiver Monographs 2004-2012.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">B.N. Nalluri, M.R. Krishna. Effect of Recrystallization on the Pharmaceutical Properties of Valsartan for Improved Therapeutic Efficacy // Journal of Applied Pharmaceutical Science (JAPS). 2012. № 2(10). P. 126-132.</mixed-citation><mixed-citation xml:lang="en">B.N. Nalluri, M.R. Krishna. Effect of Recrystallization on the Pharmaceutical Properties of Valsartan for Improved Therapeutic Efficacy // Journal of Applied Pharmaceutical Science (JAPS). 2012. № 2(10). P. 126-132.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Technical Support Forum // Сhemicalize.org. URL: http://www.chemicalize.org/structure/#!mol=valsartan&amp;source=fp (дата обращения 08.06.2016).</mixed-citation><mixed-citation xml:lang="en">Technical Support Forum // Сhemicalize.org. URL: http://www.chemicalize.org/structure/#!mol=valsartan&amp;source=fp (дата обращения 08.06.2016).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Энциклопедия лекарств и товаров аптечного ассортимента. URL: http://www.rlsnet.ru/mnn_index_id_2478.htm (дата обращения 29.05.2016).</mixed-citation><mixed-citation xml:lang="en">Энциклопедия лекарств и товаров аптечного ассортимента. URL: http://www.rlsnet.ru/mnn_index_id_2478.htm (дата обращения 29.05.2016).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">База данных методик теста «Растворение» FDA. URL: http://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm (дата обращения 10.06.2016).</mixed-citation><mixed-citation xml:lang="en">База данных методик теста «Растворение» FDA. URL: http://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm (дата обращения 10.06.2016).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Тест «Растворение» в разработке и регистрации лекарственных средств. Научно-практическое руководство для фармацевтической отрасли / Под ред. Шохина И.Е. - М.: Перо, 2015. 320 с.</mixed-citation><mixed-citation xml:lang="en">Тест «Растворение» в разработке и регистрации лекарственных средств. Научно-практическое руководство для фармацевтической отрасли / Под ред. Шохина И.Е. - М.: Перо, 2015. 320 с.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Official Monographs. Valsartan // First Supplement to USP 35-NF 30.</mixed-citation><mixed-citation xml:lang="en">Official Monographs. Valsartan // First Supplement to USP 35-NF 30.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">ОФС.1.3.0003.15. // Государственная фармакопея Российской Федерации. XIII изд.</mixed-citation><mixed-citation xml:lang="en">ОФС.1.3.0003.15. // Государственная фармакопея Российской Федерации. XIII изд.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Оценка биоэквивалентности лекарственных средств. Методические указания. Приложение 4. - М.: МЗСР РФ, 2008.</mixed-citation><mixed-citation xml:lang="en">Оценка биоэквивалентности лекарственных средств. Методические указания. Приложение 4. - М.: МЗСР РФ, 2008.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">General notes on Biopharmaceutics Classification System (BCS)-based biowaiver applications. WHO Prequalification of Medicines Programme. November 2011.</mixed-citation><mixed-citation xml:lang="en">General notes on Biopharmaceutics Classification System (BCS)-based biowaiver applications. WHO Prequalification of Medicines Programme. November 2011.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">G. Flesch, Ph. Muller, P. Lloyd. Absolute bioavailability and pharmacokinetics of valsartan, an angiotenin II receptor antagonist in man // Eur J Clin Pharmcol. 1997. № 52. P. 115-120.</mixed-citation><mixed-citation xml:lang="en">G. Flesch, Ph. Muller, P. Lloyd. Absolute bioavailability and pharmacokinetics of valsartan, an angiotenin II receptor antagonist in man // Eur J Clin Pharmcol. 1997. № 52. P. 115-120.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">N. Siddiqui, A. Husain. Pharmacological and Pharmaceutical Profile of Valsartan: A Review // Journal of Applied Pharmaceutical Science. 2011. № 1(4); P. 12-19.</mixed-citation><mixed-citation xml:lang="en">N. Siddiqui, A. Husain. Pharmacological and Pharmaceutical Profile of Valsartan: A Review // Journal of Applied Pharmaceutical Science. 2011. № 1(4); P. 12-19.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
